Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. SinoMab BioScience's Average Total Inventories for the quarter that ended in Jun. 2024 was HK$0.00 Mil. SinoMab BioScience's Revenue for the
six
months ended in Jun. 2024 was HK$2.18 Mil.
SinoMab BioScience's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.00.
SinoMab BioScience's Inventory-to-Revenue for the quarter that ended in Jun. 2024
stayed the same
from Dec. 2023 (0.00) to Dec. 2023 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
SinoMab BioScience's Days Inventory for the
six
months ended in Jun. 2024 was 0.00.
Inventory Turnover measures how fast the company turns over its inventory within a year.
SinoMab BioScience Inventory-to-Revenue Historical Data
The historical data trend for SinoMab BioScience's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SinoMab BioScience's Inventory-to-Revenue
For the Biotechnology subindustry, SinoMab BioScience's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SinoMab BioScience's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
SinoMab BioScience's Days Inventory for the
six
months ended in Jun. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of SinoMab BioScience's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:03681 has been successfully added to your 